# Grant funding data report 2019/20 

March 2021

## Key points

- Wellcome's current grant portfolio has increased in total value by $38 \%$ (from $£ 3,725 \mathrm{~m}$ to $£ 5,150 \mathrm{~m}$ ) since 2015/16.
- Our current international grant portfolio has grown by $128 \%$ (from $£ 696 \mathrm{~m}$ to $£ 1,586 \mathrm{~m}$ ) since 2015/16, and now accounts for $31 \%$ of our total grant portfolio.
- Our funding is concentrated within a few organisations. $75 \%$ of our grant portfolio is held by 20 organisations, and $38 \%$ is held by University of Oxford, Wellcome Sanger Institute, University of Cambridge and University College London.
- 704 grants worth a total of $£ 1,015 \mathrm{~m}$ were awarded in 2019/20. 369 of these grants, totalling $£ 306 \mathrm{~m}$, were awarded on our standard response-mode schemes.
- We received 3,584 applications in 2019/20, a reduction of $47 \%$ from the previous year. This is due to the closure of many of our high-volume, low-value award schemes, which have been replaced by block awards or third-party funding.
- The overall applicant success rate for competitively assessed schemes was 11\% in 2019/20 - down from 15\% in 2015/16. Success rates for men and women were the same, but those for UK-based Black, Asian and minority ethnic (BAME) applicants (8\%) were significantly lower than for UK-based White applicants (14\%), with Black applicants having the lowest success rates. Women and BAME applicants were less likely than men and White applicants to apply for higher value or more senior schemes.


## Headline facts and figures: 2019/20



## Current Portfolio

£5.1bn
Value of the current grant portfolio, an increase of $38 \%$ ( $£ 1.4 \mathrm{bn}$ ) over the past five years


Number of awards in our current grant portfolio, an increase of $8 \%$ over the past five years

$74 \%$ of our grant portfolio is in Science; $9 \%(£ 456 \mathrm{~m})$ is in Innovations;
$4 \%(£ 221 \mathrm{~m})$ is in Culture \& Society; $6 \% ~(£ 292 \mathrm{~m}$ ) is in priority areas; $5 \%$ ( $£ 249 \mathrm{~m}$ ) is in Wellcome Leap; $2 \%$ (£99m) is cross-divisional


## Applications \& Awards



Requested in 2019/20 for grant funding, from 3,584 preliminary and full grant applications


Decrease in number of applications in 2019/20


Award rate in 2019/20, down from 15\% five years ago (including preliminary and full applications)


Funding committed in 2019/20, on 704 grants


## People we fund

## 15,000

People supported on our grants (12,000 UK, 3,000 in other countries)

$$
46 \%
$$

Proportion of grant awards in 2019/20 made to women (the award rates for men and women are the same)


Award rate for UK-based BAME applicants in 2019/20, compared with $14 \%$ for UK-based White applicants


Places we fund


Organisations funded in 91 countries, including 242 UK organisations (76 of which are higher education institutions)

## $£ 1.6 \mathrm{bn}$

$31 \%$ of the grant portfolio funds international research

## £3.9bn

$75 \%$ of the grant portfolio is held by 20 organisations

## Current portfolio in 2019/20

## Grant portfolio value by area of activity



Infectious disease and immunobiology
Genomics, genetics and epigenetics*
Development and ageing
Cross-area activities**

Neuroscience and mental health

- Population, environment and health
Cultural and social contexts of health
- The distribution of our current grant portfolio between areas of activity and types of grant has changed little since $2015 / 16$. Funding has risen by over $25 \%$ for all activities.

Grant portfolio value by Division and budget


D Science (Primary Fund)*

- Innovations (Primary Fund)

Driority Areas (Reserve Fund)
Wellcome Leap (Reserve Fund)

Grant portfolio value by type of support


| People | Miscellaneous |
| :--- | :--- |
| Teams | Resources |
| Places* | Seed Funding |

* $£ 518 \mathrm{~m}$ in core support for the Wellcome Sanger Institute.
** Includes India Alliance, Diamond Light Source, Stevenage Bioscience Catalyst, Open Access block awards, Institutional Strategic Support Fund, Institutional Translational Partnership Awards and Wellcome Leap


## Portfolio trends

## Our grant portfolio has risen steadily over time

Grant portfolio value at 1 October 2015-2020


Wellcome Leap
Culture \& Society
Priority Areas

## Innovations

D Science

An increasing proportion of funding
is spent on international activities
International grant portfolio value at 1 October 2015-2020


Direct
Indirect

Grant support for research outside the UK has risen by $128 \%$ over the past five years, from $£ 696 \mathrm{~m}$ to $£ 1,586 \mathrm{~m}$. This increase is largely driven by:

- Larger-value core funding renewals for the Africa and Asia Programmes.
- One-off international initiatives (CEPI, CARB-X, DELTAS, H3Africa, Wellcome Leap, Zika and Ebola research support initiatives).
- An increase in international team awards (e.g. Collaborative Awards).


## Funding committed in 2019/20



This data captures the activities we support through our grants and awards. The figures differ from those in our Annual Report and Financial Statements because they:

- include full commitment values for awards made as Programme Related Investments
- exclude directly funded activities, including Wellcome Collection
exclude supplements, funds written back and other adjustments
Full information about our funding each year is in our Annual Report and Financial Statements.


## Funding trends

## Funding fluctuates from year to year <br> depending on timing of major commitments

Over the past five years our funding has been committed as follows:

- $40 \%$ ( $£ 1,845 \mathrm{~m}$ ) on open competitive mode calls
(e.g. Collaborative Awards, Investigator Awards, Fellowships).
- $3 \%(£ 144 \mathrm{~m})$ on thematic ring-fenced open mode funding (e.g. coronavirus, Ebola \& Zika initiatives, Global Health Trials, discretionary awards)
- $48 \%(£ 2,047 \mathrm{~m}$ ) on long-term strategic investments (Sanger, Wellcome Leap, Centres, Africa \& Asia Programmes, Innovations Flagships and Priorities, India Alliance, Diamond, Biobank, PhD Programmes, ISSF)
- $9 \%$ ( $£ 401 \mathrm{~m}$ ) on Priority Areas (e.g. Vaccines, Drug Resistant Infections, Our Planet Our Health).

Funding committed by mechanism


D Priority Areas
Ring-fenced open mode

Long term strategic investments
Open competitive mode

## Funding trends

## Application numbers fell substantially in 2019/20



Terminated schemes
Current schemes

- In 2019/20 we received 3,584 preliminary and full applications and made 704 awards.
- The number of applications fell by $47 \%$ in $2019 / 20$, due to the closure of several low-value award schemes: Vacation Scholarships, Seed funding, HSS Small Grants, Public Engagement Fund. These activities are now supported through block awards or third party funding.
- The total amount requested in applications in 2019/20 fell by $8 \%$ (from $£ 3,868 \mathrm{~m}$ to $3,556 \mathrm{~m}$ ).


## Award rates have declined over time

## Award rates



- Investigator Awards \& Senior Fellowships
- Intermediate Fellowships

Early Career Fellowships
Collaborative Awards
Over the past five years:

- The award rate for applications (including the preliminary stage) for all currently active schemes has fallen from $15 \%$ to $11 \%$.
- The award rate for full applications only has also fallen, from $24 \%$ to $20 \%$.


## Funding trends

## We fund fewer low-value awards

## Number and percentage of awards by value


£100k or more
Under £100k

Over the past five years, the proportion of awards for less than $£ 100,000$ has fallen from $53 \%$ in 2015/16 to $16 \%$ in 2019/20, following the closure of low-value, high-volume schemes (Vacation Scholarships, Seed Awards, HSS Small Grants, Public Engagement Fund).

## The value of awards has risen by up to $15 \%$

## Average award value by scheme



Early Career Fellowships
D Investigator Awards \& Senior Fellowships
Intermediate Fellowships
Collaborative Awards

Over the past five years:

- The average value of Investigator Awards and Senior Fellowships has by $15 \%$.
- We have increased the average value of Early Career Fellowships by $10 \%$.
- Average award values for other types of funding have changed little.
- Costs requested on applications have shown the same trends.


## People we fund

## The age profile of our awardees has not changed

## Number and percentage of awardees by age range



| - 60+ | - 40-49 | <29 |
| :---: | :---: | :---: |
| - 50-59 | - 30-39 |  |

Over the past four years:

- The median age of awardees for most competitively assessed schemes has not significantly changed (e.g. Investigator Award recipients 49-50 years; Senior Fellows 43-44; Intermediate Fellows 37-38; Early Career Fellows 32-34).
- Wellcome has also funded nearly 800 students awarded directly by our PhD Programmes during the past four years who are not included in the figures above. $70 \%$ of these PhD students are aged $<29$.


## The proportion of awardees who identify as disabled remains very low

## Percentage of disabled awardees*



- $3.8 \%$ of applicants ( $n=122$ ) for competitively assessed awards in 2019/20 identified as disabled. This is slowly increasing although we do not know if this reflects a greater proportion of disabled applicants or higher disclosure rates. To compare, approximately 4.5\% of UK academic staff identify as disabled (2018-19 HESA data), and the UK government estimates $19 \%$ of working age adults are disabled.
- Over the past four years, the success rate for disabled applicants (10.7\%) is lower than for non-disabled applicants (13.4\%). The small number of disabled applicants and awardees prevents more detailed analyses.
*Based on 367 awards. Data on age missing for 4.5\%
and disability missing for $3.5 \%$ of competitively assessed
awards. Data on applications and awards made on
schemes discontinued in 2018/19 has not been included


## People we fund

## Women receive $43 \%$ of awards

## Percentage of awards made by gender



Women
Prefer not to say

- Over the past four years, women have received $43 \%$ of competitively assessed awards ( $35.9 \%$ in Science, $68.9 \%$ in Culture \& Society).
- The overall success rates for men (13.0\%) and women (12.7\%) are not significantly different over the past four years.


## Women receive fewer grants above $£ 1 \mathrm{~m}$

Percentage of awards for $£ 1 \mathrm{~m}$ or more by gender


D Men
Women

- Women make up a smaller proportion of applicants and awardees for more senior level awards and those with higher financial value on competitively assessed schemes. As a consequence, men are awarded more than twice the total amount of funding as women per year (e.g. in 2019/20, men were awarded c. $£ 250 \mathrm{~m}$, women $£ 115 \mathrm{~m}$ ). At scheme level, on average men request and are awarded 10-15\% more funding on Science competitively assessed schemes.


## People we fund

## BAME, and particularly Black, researchers are underrepresented among UK-based awardees

## Ethnicity of awardees*



Asian
Other
Not known

For competitively assessed awards based at UK organisations (excluding international schemes) over the past four years:

- The proportion of Black, Asian and minority ethnic (BAME) applicants rose from $14.8 \%$ to $18.2 \%$. The proportion of BAME awardees has fluctuated but not increased. In 2019/20 no awards were made to applicants reporting their ethnicity as Black or Black British. To compare, 14\% of the population in the UK 2011 census were BAME, and 17\% of UK academic staff are BAME (2018-19 HESA data).


## Success rates for BAME applicants remain lower than for White applicants

## Award rate by ethnicity



## bame

White

- Success rates are lower for BAME applicants (10.3\%) than for White applicants (16.1\%). Success rates are similar for BAME men and women. Success rates are lowest for Black applicants (8.6\%).
BAME researchers make up a smaller proportion of applicants and awardees for more senior awards and those with higher financial value.
If international schemes and awards to non-UK based organisations are included, over the past four years $28.6 \%$ of applicants and $19.3 \%$ of awardees are BAME. Award rates are $9.6 \%$ for BAME applicants and $15.3 \%$ for White applicants.


## Places we fund worldwide

## Funding by country



- $31 \%$ of our current grant portfolio supports research in 91 countries outside the UK.
- $17 \%$ of the portfolio ( $£ 850 \mathrm{~m}$ ) has been awarded directly to organisations outside the UK (including £125m CARB-X, £120m India Alliance, £120m African Academy of Sciences and £81m CEPI).
- 14\% (£736m) has been awarded indirectly through UK institutions for research carried out in other countries (including $£ 249 \mathrm{~m}$ to Wellcome Leap, and $£ 171 \mathrm{~m}$ to the Africa and Asia Programmes in Thailand, Vietnam, Kenya, Malawi and South Africa).

| Over $£ 50 \mathrm{~m}$ | £1m-£10m |
| :--- | :--- |
| £10m-£50m | Up to $£ 1 \mathrm{~m}$ |

## Places we fund worldwide

## UK organisations with more than $£ 25 \mathrm{~m}$ in grant funding



## London organisation fundin

University College London - £407m

Wellcome Leap Inc. - £249m

- Imperial College London - £181m

King's College London - £163m

The Francis Crick Institute - £125m

London School of Hygiene \& Tropical Medicine - £77m

Medical Research Council - £54m

Queen Mary University o London - £30m
Academy of Medical Sciences - £29m

## UK funding is concentrated in a few places

- $85 \%$ of our grant portfolio is held by UK organisations.
- $38 \%$ of our grant portfolio is held by four organisations: University of Oxford, Sanger Institute, University of Cambridge, University College London.
- Several UK higher education institutions - including Oxford, Cambridge, UCL, Dundee, Birkbeck, Liverpool School of Tropical Medicine, and London School of Hygiene \& Tropical Medicine - receive at least 15\% of their total research grant income from Wellcome.

Funding to the Medical Research Council (MRC) includes:

- awards made for activities conducted at MRC Research Institutes (e.g. Laboratory of Molecular Biology Cambridge)
- funding awarded directly to MRC to administer joint initiatives (e.g. our $£ 15 \mathrm{~m}$ contribution to the Global Health Trials Initiative).


## Advisory committees and peer review

We are close to achieving our targets for women and BAME representation on our advisory committees

Gender of 2019/20 advisory committee membership by division


Not known
Prefer not to say

- We currently have 377 members of 36 advisory committees.
- In 2019 we introduced targets for committee member diversity to reach in 2021. These targets and the current rates are:
- Gender: target 50\% women; current 48\%
- Ethnicity: target 15\% BAME, current 15\%
- Location: target 25\% non-HEI, current 20\%
- Location: target 30\% non-UK, current 39\%.

We also have a target for disability, but the target and current numbers are too low to disclose publicly.

## Peer review requests are falling

Peer review requests and reviews received


Peer review requests
Response rate
Over the past five years, the number of peer review requests has fallen, because:

- overall application numbers have fallen
- for many schemes, we now use our Expert Review Groups to shortlist applications before seeking external peer review
- clinical PhD support is now assessed at a programme level, not individually.
- $39 \%$ of peer review requests are sent to North American reviewers, $30 \%$ to UK reviewers, $19 \%$ to European reviewers and $12 \%$ elsewhere.
- We get the highest response from UK reviewers (60\%) and the lowest response from North American reviewers (35\%).

Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we're taking on three worldwide health challenges: mental health, global heating and infectious diseases.

